Lexeo Financial Statements From 2010 to 2026

LXEO Stock

9.44 0.17 1.77%

Lexeo Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Lexeo Therapeutics' valuation are provided below:

Gross Profit

-66 M

Market Capitalization

701.4 M

Enterprise Value Revenue

416.3418

Earnings Share

(2.50)

We have found one hundred twenty available fundamental ratios for Lexeo Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Lexeo Therapeutics' last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 6th of January 2026, Market Cap is likely to grow to about 212.1 M, while Enterprise Value is likely to drop about 154.3 M.

Lexeo Therapeutics Total Revenue

0.0

Check Lexeo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexeo Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9 M or Depreciation And Amortization of 2.4 M, as well as many indicators such as Price To Sales Ratio of 377, Dividend Yield of 0.0 or PTB Ratio of 1.69. Lexeo financial statements analysis is a perfect complement when working with Lexeo Therapeutics Valuation or Volatility modules.

Build AI portfolio with Lexeo Stock

Check out the analysis of Lexeo Therapeutics Correlation against competitors.

Lexeo Therapeutics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

121 M

169 M

66.7 M

Slightly volatile

Short and Long Term Debt Total

10.5 M

11.4 M

6.1 M

Slightly volatile

Other Current Liabilities

8.2 M

15.8 M

3.9 M

Slightly volatile

Total Current Liabilities

13.8 M

26.3 M

6.4 M

Slightly volatile

Current Deferred Revenue

12.9 M

12.3 M

3.3 M

Slightly volatile

Accounts Payable

7.7 M

7.4 M

1.9 M

Slightly volatile

Cash

29.9 M

31.5 M

44.4 M

Slightly volatile

Non Current Assets Total

12.7 M

23.9 M

5.6 M

Slightly volatile

Non Currrent Assets Other

3.1 M

3.7 M

1.2 M

Slightly volatile

Cash And Short Term Investments

106.8 M

139.7 M

60.3 M

Slightly volatile

Common Stock Shares Outstanding

29.5 M

36.6 M

26.6 M

Slightly volatile

Liabilities And Stockholders Equity

121 M

169 M

66.7 M

Slightly volatile

Non Current Liabilities Total

6.2 M

6.5 M

46.3 M

Very volatile

Other Current Assets

5.6 M

5.3 M

1.3 M

Slightly volatile

Other Stockholder Equity

479.5 M

456.7 M

106.9 M

Slightly volatile

Total Liabilities

25.7 M

27.1 M

52.7 M

Pretty Stable

Total Current Assets

109.2 M

145 M

61.5 M

Slightly volatile

Capital Stock

2.6 K

3.5 K

2 K

Slightly volatile

Net Working Capital

95.5 M

118.8 M

55 M

Slightly volatile

Short Term Debt

2.8 M

3.1 M

1.4 M

Slightly volatile

Common Stock

2.5 K

3.5 K

2 K

Slightly volatile

Lexeo Therapeutics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

2.4 M

2.3 M

574.7 K

Slightly volatile

Selling General Administrative

38.2 M

36.4 M

8.8 M

Slightly volatile

Other Operating Expenses

64.4 M

121.6 M

31.2 M

Slightly volatile

Research Development

49.7 M

85.2 M

23.8 M

Slightly volatile

Total Operating Expenses

64.4 M

121.6 M

31.2 M

Slightly volatile

Interest Income

9.2 M

8.7 M

1.8 M

Slightly volatile

Selling And Marketing Expenses

2.2 M

2.1 M

590.3 K

Slightly volatile

Cost Of Revenue

1.4 M

2.3 M

519.4 K

Slightly volatile

Lexeo Therapeutics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Change In Working Capital

2.7 M

3.1 M

1.1 M

Slightly volatile

Begin Period Cash Flow

81.5 M

143.4 M

35.1 M

Slightly volatile

Issuance Of Capital Stock

81.4 M

102 M

50.2 M

Slightly volatile

Total Cash From Financing Activities

82.7 M

102.1 M

52 M

Slightly volatile

End Period Cash Flow

41.8 M

44 M

46.4 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

377

445

441

Slightly volatile

Average Payables

1.2 M

1.4 M

1.5 M

Slightly volatile

Stock Based Compensation To Revenue

2.57

2.45

0.9403

Slightly volatile

Capex To Depreciation

0.26

0.28

9.9972

Slightly volatile

EV To Sales

292

333

375

Slightly volatile

Payables Turnover

0.25

0.28

0.1063

Slightly volatile

Sales General And Administrative To Revenue

17.34

16.52

6.4675

Slightly volatile

Research And Ddevelopement To Revenue

71.04

67.65

28.4154

Slightly volatile

Capex To Revenue

1.3

1.24

0.4726

Slightly volatile

Cash Per Share

2.88

3.44

2.1182

Slightly volatile

Days Payables Outstanding

1.3 K

59.2 K

Slightly volatile

Income Quality

0.66

0.74

0.6826

Slightly volatile

Net Debt To EBITDA

0.28

0.3

4.0872

Slightly volatile

Current Ratio

6.03

6.35

30.1561

Slightly volatile

Capex Per Share

0.0177

0.0174

0.0107

Slightly volatile

Revenue Per Share

0.03

0.0234

0.0249

Slightly volatile

Interest Debt Per Share

0.29

0.28

0.2229

Slightly volatile

Debt To Assets

0.11

0.0777

0.1025

Pretty Stable

Days Of Payables Outstanding

1.3 K

59.2 K

Slightly volatile

Ebt Per Ebit

1.1

1.07

1.0825

Slightly volatile

Quick Ratio

6.03

6.35

30.1561

Slightly volatile

Cash Ratio

1.67

1.76

29.3366

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.11

1.16

1.0204

Slightly volatile

Fixed Asset Turnover

0.0519

0.0546

6.7368

Slightly volatile

Debt Ratio

0.11

0.0777

0.1025

Pretty Stable

Price Sales Ratio

377

445

441

Slightly volatile

Asset Turnover

0.0134

0.0077

0.0146

Slightly volatile

Lexeo Therapeutics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

212.1 M

188.2 M

250.3 M

Pretty Stable

Enterprise Value

154.3 M

165.7 M

208.9 M

Slightly volatile

Lexeo Fundamental Market Drivers

Lexeo Upcoming Events

	4th of November 2024 Upcoming Quarterly Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	4th of November 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Lexeo Therapeutics Financial Statements

Lexeo Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Lexeo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	12.3 M	12.9 M
Cost Of Revenue	2.3 M	1.4 M
Stock Based Compensation To Revenue	2.45	2.57
Sales General And Administrative To Revenue	16.52	17.34
Research And Ddevelopement To Revenue	67.65	71.04
Capex To Revenue	1.24	1.30
Revenue Per Share	0.02	0.03
Ebit Per Revenue	(106.40)	(101.08)

Pair Trading with Lexeo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lexeo Stock

0.67

GILD

Gilead Sciences

Pair Corr

Moving against Lexeo Stock

0.71	MGMA	Metro Global Media	Pair Corr
0.54	HD	Home Depot	Pair Corr
0.42	PG	Procter Gamble	Pair Corr
0.39	MSFT	Microsoft Sell-off Trend	Pair Corr
0.37	HPQ	HP Inc	Pair Corr

The ability to find closely correlated positions to Lexeo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics Common to buy it.

The correlation of Lexeo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Lexeo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Lexeo Therapeutics Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexeo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexeo Therapeutics Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexeo Therapeutics Common Stock:

How To Invest In Lexeo

Details

Is Lexeo Stock a good investment?

Details

What is Lexeo Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Lexeo Therapeutics Correlation against competitors.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.50)

Return On Assets

(0.45)

Return On Equity

(0.81)

The market value of Lexeo Therapeutics Common is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics' market value can be influenced by many factors that don't directly affect Lexeo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lexeo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Lexeo Financial Statements From 2010 to 2026

Lexeo Therapeutics Total Revenue

0.0

Lexeo Therapeutics Balance Sheet

Lexeo Therapeutics Income Statement

Lexeo Therapeutics Cash Flow Statement

Financial Ratios

Lexeo Therapeutics Valuation Data

Lexeo Fundamental Market Drivers

Lexeo Upcoming Events

About Lexeo Therapeutics Financial Statements

Pair Trading with Lexeo Therapeutics

Moving together with Lexeo Stock

Moving against Lexeo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY